Certain cancers more common among HIV patients than non-HIV patientsSeptember 25, 2009Researchers at UT Southwestern Medical Center have found that non-AIDS-defining malignancies such as anal and lung cancer have become more prevalent among HIV-infected patients than non-HIV patients since the introduction of anti-retroviral therapies in the mid-1990s. AIDS patients with suppressed immune systems are at higher risk for so-called AIDS-defining malignancies - cancers such as non-Hodgkin's lymphoma, Kaposi's sarcoma and cervical carcinoma. Some researchers have speculated, however, that HIV patients are diagnosed with more non-AIDS-defining malignancies simply because anti-retroviral drugs now used enable them to live longer, but the results of the UT Southwestern study suggest that other factors may be at work. The researchers, using data from more than 100,000 patient records in the U.S. Veterans Affairs Healthcare System, found that when the statistics were adjusted for gender, race/ethnicity and age, HIV-infected patients were 60 percent more likely to have anal, lung, Hodgkin's, melanoma or liver cancer than patients without HIV. The rate of prostate cancer was similar between the two groups, according to the report. "It's a genuine increase in the incidence of these cancers," said Dr. Roger Bedimo, assistant professor of internal medicine at UT Southwestern and lead author of a study appearing online and in the October edition of the Journal of Acquired Immune Deficiency Syndromes. "The increase is more visible because these patients are living longer, but our findings suggest that the increased number of non-AIDS-defining malignancies is not simply the result of their longer lives." For the study, researchers compared the rates of non-AIDS-defining malignancies between patients with and without HIV who received care at a VA system facility between 1997 and 2004. For each HIV-positive patient, researchers identified at least two HIV-negative patients who received care the same year and matched them on age, sex, race and geographic location. The final study population included 33,420 HIV-infected patients and 66,840 non-infected patients. The non-AIDS-defining malignancies included all forms of cancer except skin, lymphoma, cervical carcinoma, Kaposi's sarcoma and ill-defined cancers. Dr. Bedimo said the researchers examined anal, lung, melanoma, prostate, Hodgkin's and liver cancers - all non-AIDS-defining - individually. Dr. Bedimo, chief of infectious disease at the Veterans Affairs North Texas Health Care System, said it's unclear exactly why non-AIDS-defining malignancies are more common in HIV patients than the general population. One controversial theory, he said, is that the anti-retroviral therapy itself might increase the risk of those cancers in HIV patients. "The second hypothesis is that HIV-infected patients somehow, either by their lifestyle or other circumstances, are more subject to the traditional risk factors than non-HIV patients," he said. "The third hypothesis is that HIV or another undetected virus increases a patient's risk for developing cancer intrinsically." Dr. Bedimo said that one major limitation of the study is the overrepresentation of males in the study. Males account for about 98 percent of the study population. The next step is for researchers to examine other measures of immune function in patients with and without cancer. "The hallmark of chronic HIV is a decline in CD4 T-cells, but we also know that HIV does a lot more to your immune system than just decrease the number of these cells," Dr. Bedimo said. "It's very possible that it is an immune dysfunction that impairs the cancer immune surveillance in patients even after their CD4 counts have increased." UT Southwestern Medical Center |
|||||||||||||||||||||
| Related HIV Current Events and HIV News Articles Many pregnant women avoid HIV screening in Africa 'Prevention is the best cure' is a common expression, but what happens if preventative measures are not used? A large proportion of pregnant Ugandan women are going out of their way not to be HIV tested, increasing the risk of mother-to-child transmission. An atomic-level look at an HIV accomplice Since the discovery in 2007 that a component of human semen called SEVI boosts infectivity of the virus that causes AIDS, researchers have been trying to learn more about SEVI and how it works, in hopes of thwarting its infection-promoting activity. New findings suggest strategy to help generate HIV-neutralizing antibodies New discoveries about anti-HIV antibodies may bring researchers a step closer to creating an effective HIV vaccine, according to a new paper co-authored by scientists at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Research calls for better assessment of tests for tuberculosis, HIV/AIDS and malaria A rapid and accurate diagnosis is the first step towards treatment in the fight against infectious disease. No-entry zones for AIDS virus The AIDS virus inserts its genetic material into the genome of the infected cell. Scientists of the German Cancer Research Center have now shown for the first time that the virus almost entirely spares particular sites in the human genetic material in this process. This finding may be useful for developing new, specific AIDS drugs. Hoping for a fluorescent basket case Although recent advances have raised hopes that a protective vaccine can be developed, acquired immunodeficiency syndrome (AIDS) remains a major public health problem. Scientists explain binding action of 2 key HIV antibodies; could lead to new vaccine design A very close and detailed study of how the most robust antibodies work to block the HIV virus as it seeks entry into healthy cells has revealed a new direction for researchers hoping to design an effective vaccine. U.S. and European Experts Applaud Creation of New Transatlantic Task Force on Global Antibiotic Resistance Threat Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide. 1930s drug slows tumor growth Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. Indiana U. at APHA: Studies about why men and women use lubricants during sex An Indiana University study involving 2,453 women ages 18 to 68 found that lubricant use during sexual activity alone or with a partner contributed to higher ratings of pleasurable and satisfying sex. More HIV Current Events and HIV News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||